Fat stem cells infused into kidney artery to fight transplant rejection

NCT ID NCT05456243

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This early-stage trial tests whether a single infusion of stem cells from donated fat tissue can safely treat rejection in kidney transplant recipients. The cells are delivered directly into the kidney artery. The study includes 12 adults with biopsy-proven rejection and aims to check for side effects and worsening rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adipose-derived mesenchymal stromal cells (fat stem cells)
What this could lead to: If it works, this could offer a new way to treat kidney transplant rejection without stronger immune-suppressing drugs.
What could go wrong: This is a very early Phase 1 safety trial with only 12 people. The treatment may not work or could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELLULAR REJECTION IN KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.